Enovis Corporation ENOV 深 沪
等待开盘 01-22 09:30:00 美东时间
23.68
+0.590
+2.56%
华盛通- 最 高23.90
- 今 开23.26
- 成交量 98.08万股
- 最 低 23.11
- 昨 收 23.09
- 总市值 13.54亿
- 52周最高 47.26
- 市盈率 静 --
- 换手率 1.72%
- 52周最低 22.98
- 委 比 -43.18%
- 总股本 5718.94万
- 历史最高 176.11
- 量 比 0.84
- 振 幅 3.42%
- 历史最低 -13.31
- 每 手 1
- 风险率 5.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to b...
01-21 19:41
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
BTIG Initiates Coverage On Enovis with Buy Rating, Announces Price Target of $41
BTIG analyst Ryan Zimmerman initiates coverage on Enovis (NYSE:ENOV) with a Buy rating and announces Price Target of $41.
01-06 19:31
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Freedom Capital Markets Initiates Coverage On Enovis with Buy Rating, Announces Price Target of $45
Freedom Capital Markets analyst Keith Hinton initiates coverage on Enovis (NYSE:ENOV) with a Buy rating and announces Price Target of $45.
2025-12-17 17:19
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
Wells Fargo Maintains Overweight on Enovis, Raises Price Target to $42
Wells Fargo analyst Vik Chopra maintains Enovis (NYSE:ENOV) with a Overweight and raises the price target from $41 to $42.
2025-11-08 02:51
Enovis Raises FY2025 Adj EPS Guidance from $3.05-$3.20 to $3.10-$3.25 vs $3.12 Est; Lowers FY2025 Sales Guidance from $2.245B-$2.275B to $2.240B-$2.270B vs $2.255B Est
Enovis (NYSE:ENOV) raises FY2025 Adj EPS guidance from $3.05-$3.20 to $3.10-$3.25 vs $3.12 analyst estimate. Lowers FY2025 sales outlook from $2.245 billion-$2.275 billion to $2.240 billion-$2.270 billion vs $2.255
2025-11-06 19:05
Enovis Q3 Adj. EPS $0.75 Beats $0.65 Estimate, Sales $548.912M Beat $538.617M Estimate
Enovis (NYSE:ENOV) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.65 by 15.56 percent. This is a 2.74 percent increase over earnings of $0.73 per share from the same period
2025-11-06 19:03
